Artificial Intelligence News: DeepMind’s AlphaGenome 2
The biggest artificial intelligence news of the week comes from a laboratory rather than a chatbot. Google DeepMind announced AlphaGenome 2 on November 11, 2026, a new deep-learning model that predicts how changes in DNA affect gene activity inside specific human cell types. The announcement matters because it attacks one of the oldest blind spots in genetics: the same DNA variant can behave very differently depending on the cell it sits in, and until now most AI tools for reading the genome have averaged that behaviour away. A variant that quietly switches a gene on inside a gut immune cell may do nothing at all in the skin or liver cells around it, and a model that only looks at whole tissues will miss it entirely. AlphaGenome 2 is built to stop missing it.
The release arrives as artificial intelligence news is increasingly about specialised tools rather than general-purpose chatbots. DeepMind's first AlphaGenome, launched last year, could already predict how DNA variants affect molecular activity across broad tissues, and in September 2026 the company added AlphaGenome Atlas, a platform holding predictions for all 9 billion possible single-letter changes in the human genome. AlphaGenome 2 goes further by asking a question the earlier tools could not answer precisely: in which exact cell does this variant act, and what does it do there? According to DeepMind, the new model identifies nearly twice as many variants that change gene expression in cells as the company's previous leading model, a claim that, if it holds up in independent testing, could reshape how scientists hunt for the cellular drivers of disease.
AI News: How AlphaGenome 2 Reads DNA Cell by Cell
The central idea behind AlphaGenome 2 is simple to state and difficult to build. Instead of feeding the model a DNA sequence and asking it to predict everything at once, DeepMind redesigned the system so that it takes a specific biological condition alongside the sequence. That condition can be a tissue, a cell type or a cell state, chosen from a reference catalogue or generated on the fly from a scientist's own single-cell experiment. The model then predicts gene regulation for that one condition at a time, using the condition as an input at every stage of its architecture, from the earliest layers to the final outputs.
The difference from the first AlphaGenome is architectural. The original model took a DNA sequence of up to a million letters and predicted properties across thousands of experiments from many tissues all at once. That parallel approach was efficient, but it spread the model's capacity thin and made it hard to capture the subtle differences between closely related cell types. AlphaGenome 2 concentrates its full attention on one condition at a time, which allows it to learn how the same stretch of DNA is read differently across cell types. In practice, a researcher can select a cell type, score candidate variants, compare the predicted shifts in gene expression and prioritise which laboratory experiments to run next.
The model predicts the same core readouts of DNA function as its predecessor, including gene expression, histone modifications and chromatin accessibility, and it adds DNA methylation, a widely requested readout that the first version did not offer. It was trained on both bulk and single-cell data from human and mouse samples. That training data is the foundation of the model's claim to cell-level resolution: by learning from such a vast collection of individual cells, the system can resolve activity inside specialised cells, such as distinct heart muscle or blood immune cells, and uncover DNA variants that act only in those specific places.
Science News Today: The Benchmarks Behind the Claims
In today's science news, the numbers attached to a new AI model matter as much as the idea behind it, and DeepMind has published detailed benchmark figures for AlphaGenome 2. The headline test used TenK10K, a large single-cell map of 28 primary immune cell types. On that dataset, the company reports that AlphaGenome 2 identified 30 percent of putatively causal expression variants at 90 percent precision, compared with 16 percent for the original AlphaGenome fine-tuned on single-cell data. It also recovered 43 percent of directional gene effects, meaning cases where the model correctly predicted whether a variant turns a gene's activity up or down, against 23 percent for the earlier system. In other words, the new model found nearly twice as many of the variants that change gene expression, and it was also better at predicting the direction of the change.
Those figures are company-reported, and independent replication has not yet appeared, a caveat that applies to most major model launches. But DeepMind has also offered concrete examples of the model reproducing known biology. A recent landmark study showed that a variant in a distant regulatory switch drives inflammatory bowel disease by overactivating the ETS2 gene in gut immune cells known as macrophages. Making predictions across various immune cell types in the gut, AlphaGenome 2 reproduced that finding computationally: it singled out the causal variant and showed that it selectively boosts the ETS2 gene in gut macrophages, leaving other cell types and genes largely unaffected. That kind of precision is exactly what researchers need when they are trying to connect a genetic association to a mechanism they can test in the laboratory.
Technology News: From the First AlphaGenome to a Cell Atlas
To understand why AlphaGenome 2 matters, it helps to retrace the short history of the project. DeepMind launched the first AlphaGenome in June 2025, and the work was published in the journal Nature in January 2026. The original model predicted molecular activity across broad tissues, and it quickly became a tool for researchers trying to interpret the flood of variants emerging from genome-wide association studies. Those studies routinely flag broad stretches of DNA linked to disease, but they cannot by themselves identify the exact cell where a variant acts, which is often the missing piece of the puzzle.
In September 2026, DeepMind expanded the project's reach with AlphaGenome Atlas, a platform containing predictions for all 9 billion possible single-letter changes in the human genome. The atlas gave researchers a ready-made reference they could consult without running large-scale computations themselves. AlphaGenome 2 is a separate model release rather than an extension of that precomputed atlas, and DeepMind has been clear about why a new atlas was not built on top of it: predictions from the new model cost more compute than the original, which makes a genome-wide atlas impractical for now. The original AlphaGenome will stay in service, and the two systems are intended to complement each other rather than compete.
The November 11 announcement fits into a wider pattern of technology news in which the most consequential AI releases are increasingly specialised. DeepMind says it will soon release AlphaGenome 2 Skills in Google Antigravity, its agentic development platform, where specialised models will work alongside Gemini 4 to help scientists accelerate research. That is notable Google Gemini news in its own right, because it shows how DeepMind intends to combine narrow, scientifically validated models with general-purpose AI agents, rather than asking one system to do everything. The data center news angle matters here too: models like AlphaGenome 2 are computationally demanding, and the infrastructure that trains and serves them, from high-performance computing clusters to the power grids that feed them, has become a central part of the story of modern AI research.
Reactions: Researchers Welcome Sharper Genetic Leads
Reaction to the launch has been positive but measured, with researchers welcoming the sharper resolution while noting that the real test will come when independent laboratories put the model through its paces. Genomics Limited chief executive Peter Donnelly said he looked forward to incorporating AlphaGenome 2 into the company's Mystra platform, a sign that commercial genomics firms see practical value in the cell-specific predictions. DeepMind's ongoing collaborations include researchers at the Wellcome Sanger Institute, with whom the company is working to profile an even wider spectrum of human cell types, developmental lineages and perturbed cellular states.
Independent analysts have pointed out that the headline benchmark gains, impressive as they are, still leave most causal variants unrecovered: even at 90 percent precision, the model found 30 percent of the expression-linked variants that statistical analyses nominate as likely causal, which means seven in ten remain missed on that test. That is not a flaw unique to AlphaGenome 2; it reflects how hard the underlying biology is. But it is a reminder that the model is a prioritisation tool, not an oracle. Researchers will get the most from it by pairing its predictions with independent experiments such as CRISPR perturbations, external cohorts and uncertainty estimates, rather than treating a high score as proof. The company has also thanked a community of trusted testers for their feedback, and it is inviting researchers to submit use cases through a community spotlight programme, with applications closing on November 30 and selected projects potentially eligible for additional API quota and credits.
What Happens Next for AlphaGenome 2
Access is the first question most researchers will ask, and DeepMind's answer is tiered. AlphaGenome 2 is available now for non-commercial research through the AlphaGenome API, with interactive Colab tutorials for expression conditioning offered alongside it. According to the official documentation, non-commercial API use is free, with query rates varying according to demand. Commercial research, by contrast, is restricted to a private preview, with no public pricing disclosed. Unlike the first AlphaGenome, whose weights were released on GitHub for non-commercial use, the new model is being offered through the API rather than as downloadable weights, a decision that reflects both its higher computational cost and DeepMind's preference for controlling how the system is used.
The second question is what the model cannot do. DeepMind states plainly that both AlphaGenome versions are intended for research use only and have not been validated or approved for clinical or diagnostic purposes. That means AlphaGenome 2 will not read a patient's genome and deliver a diagnosis, and it should not be presented as a medical tool. Its role is to help scientists prioritise variants, design experiments and generate hypotheses about disease mechanisms, with any clinical application lying far down the road and requiring separate validation. The distinction matters in a week when artificial intelligence news is full of grand claims, and DeepMind's careful wording is a reminder that a research model and a clinical product are very different things.
Source: Google DeepMind